ROCKVILLE, Md. — The Emmes Group announced that its Board of Directors has appointed Rama Kondru, Ph.D., as Chief Executive Officer.
Dr. Kondru joined The Emmes Group in 2024 and most recently served as CEO of Veridix, the company’s artificial intelligence, technology and data sciences business. The company said his appointment reflects its focus on using AI, technology and scientific expertise to improve the speed and quality of clinical trials.
“It is a privilege to lead The Emmes Group at such an exciting time for our industry,” Dr. Kondru said. “For nearly five decades, Emmes has stood behind some of the most important public health efforts, from the earliest NIH vaccine and infectious disease programs to the trials that helped the world respond to COVID-19. Building on that legacy, we have a unique opportunity to combine AI, technology, and clinical expertise to transform how trials are designed and conducted.”
He added that the company aims to help customers bring new therapies to patients faster while creating long-term value for customers, employees and investors.
Before joining Emmes, Dr. Kondru served as Co-CEO of Medidata Solutions, a clinical development technology company. He brings about 25 years of experience spanning pharmaceuticals, healthcare technology, data science and academia.
Earlier in his career, he served as Senior Vice President and Chief Information Officer for Janssen Americas at Johnson & Johnson and as Vice President and Chief Information Officer for R&D and Innovation at Johnson & Johnson Medical Devices.
Dr. Kondru also held leadership roles at UCB Pharma and F. Hoffmann-La Roche.
He earned a bachelor’s degree from the Indian Institute of Technology Bombay and a Ph.D. from the University of Pittsburgh, where he also completed postdoctoral research. He has also served as an Adjunct Professor at Duke University.
